Group items matching

in title, tags, annotations or url

This program has combined previous quality reporting programs such as Physician Quality Reporting System (PQRS), Value-based Payment Modifier (VM), and the Electronic Health Records (EHR) Incentive program (Meaningful Use) under one platform.

The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with community pharmacies playing a central role in facilitating access. The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on cannabis-based medicinal products (CBPMs). The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.

Fellowship in Pediatrics in India - MediColl offering pediatric fellowship programs at an affordable fee with a highly qualified course director.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

Fellowship in Diabetes Mellitus is a programme of one year has been developed to address the gap in medical education & contact program and simulation training.

Fellowship in Family Medicine is a programme of one year is a judicious blend of practical and theoretical pedagogy wherein learners acquire rigorous theoretical knowledge of the subjects and go through clinical training of three months at reputed hospitals that allow them to acquire skills and hands-on experience under the supervision of transcendent faculty.

Find out more about health education degree programs, where you can study it online, the career and salary prospects after completion, and more ...

Detox is the first step in your outpatient drug and alcohol rehabilitation Florida. All treatment centers patients have to go through the detox. There are three stages of process of detoxification…

Nu-Leaf Retreat gives you an opportunity to escape from the stresses of your busy daily life. You can also improve fitness or change in your food habits for weight loss or you have some other health issues. Visit us for great fitness in hunter valley.

Since the healthcare industry has taken serious measures to revamp healthcare services, the emphasis on incentive payment programs has increased. MIPS and MACRA, and more offer facilities to physicians that regular payment method can never provide

Here you'll find the official resources to report MIPS 2020; P3Care has a habit of coming up with useful information about the MIPS program. As a CMS MIPS Qualified Registry, in an effort to find the most relevant content for physicians, consider it as another episode.

Under MIPS QPP (Quality Payment Program), physicians report clinical data to CMS. They reward clinicians upon their contribution to make the current healthcare system an empowered one, incorporating technology and interoperability for patients' convenience.

The US healthcare system is made up of complexities. A system in which people with disabilities and above the age of 65 are covered by Medicare and Medicaid programs, clinicians ought to make their financial cycles a priority. When it is the first thing on your to-do lists, medical claims approve at a much faster rate without having to worry about denials.

QPP MIPS reporting program of 2019 also had to face delays due to this catastrophe with overburdened staff, doctors, and suppliers associated with them any capacity. The closing date for MIPS 2019 went one-month further to facilitate clinicians busy dealing with the surge in COVID-19 patients. It was indeed a rollercoaster ride for them from the very first day

Modern medical billing services in the USA use medical billing software to accomplish their tasks. Quality payment program has allowed all medical billers and coders to use digital tools and resources for improving healthcare services. Now, healthcare service providers provide value-based services to get more payment incentive.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients. However, there are a few commonly used MIPS Quality Measures that both doctors can use and register their value-based care. Last year, the condition was a little different with MIPS data submission, but for MIPS 2021, the requirements are seen to be a bit flexible, and the corona pandemic is the reason for that. From Advance Care Plan to the MIPS Quality Measures, associated with the common illnesses and conditions, eligible clinicians have to check which measures are most suitable for their practice. An easy way to go through the process of MIPS 2021 reporting is to find a MIPS Qualified Registry. They have the resources and the trained MIPS consultants to help you meet your objectives.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients.

MIPS has elevated the way Medicare part B providers get compensated. Each category, including Promoting Interoperability, has specific measures and guidelines that need to be fulfilled for MIPS 2021 reporting.

Out of the 2,805 students who sat for the common registration assessment test for pharmacists this June, approximately 2,150 have passed the exam, according to the General Pharmaceutical Council. It assesses pharmacy graduates' knowledge and skills to ensure safe and effective practice as pharmacists. This year, the pass rate was 77 per cent, slightly lower than the 80 per cent pass rate in June 2022, where 2,147 out of 2,697 candidates cleared the assessment, GPhC data showed. The exam comprises a written assessment testing pharmaceutical science and pharmacy practice knowledge and a practical assessment evaluating clinical skills and patient-facing competencies. Eligible candidates must complete an accredited pharmacy degree program and meet GPhC requirements. The assessment is conducted jointly by the General Pharmaceutical Council and the Pharmaceutical Society of Northern Ireland. "The assessment is a primary method for testing trainees' ability to apply knowledge and make professional judgments in pharmacy practice," said Mark Voce, Director of Education and Standards, GPhC. "This is crucial in assuring patients and the public that they are in safe hands."

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.